Premium
Effect of pravastatin on markers of endothelial activation in dialysis patients
Author(s) -
JEFFS LISA S,
SKILTON FRANCES,
NITSCHKE JODIE,
BANNISTER KYM M,
FAULL RANDALL J
Publication year - 2007
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2007.00766.x
Subject(s) - pravastatin , medicine , gastroenterology , dialysis , lipid profile , endothelial activation , liver function , statin , inflammation , cholesterol
SUMMARY: Aim: The aim of this pilot study was to test the effect of pravastatin on serum levels of high‐sensitivity CRP (hs‐CRP), IL‐6 and the soluble adhesion molecules sVCAM‐1, sICAM‐1 and sE‐selectin in chronic dialysis patients. Methods: At the commencement of the study, serum levels of lipids, liver function tests and endothelial markers (CRP, IL‐6, sICAM‐1, sVCAM‐1, sE‐selectin) were measured. Patients then commenced 1 month of 10 mg of pravastatin per day, and if tolerated, then 4 months of 40 mg of pravastatin per day. Serum levels of lipids, liver function tests and endothelial markers were repeated after the total of 5 months of pravastatin therapy. Results: Thirty‐nine patients were enrolled, and 25 (male/female 17/8; 21 haemodialysis, 4 peritoneal dialysis) patients completed the study. Pravastatin therapy significantly improved the patients' lipid profiles, but had no significant effect on the levels of CRP, IL‐6, sICAM‐1, sVCAM‐1, or sE‐selectin. Conclusion: Short‐term (5 months) treatment with pravastatin in patients receiving chronic dialysis improved their lipid profile, but had no significant effect on surrogate markers of endothelial activation.